Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Somewhere out there
View:
Post by Dumbeldorfwhite on Oct 26, 2023 9:15am

Somewhere out there

BionicJoe is smiling
Comment by Donein25 on Oct 26, 2023 11:00am
Of course he is Dumbo...he has you and Budfoxx to carry on. Do you think it dawned on BJ yet that TLT will now have the cash to keep the lights on (as Bud would put it) and finish this trial with an expanded protocol that will increase CR and drive greater revenues? And then there's BTD, JV and AA, not to mention comleting preclinical work on GBM. Think he/you can comprehend all that?
Comment by Rumpl3StiltSkin on Oct 26, 2023 11:07am
  I hope you're right Donein. I dont know if they have enuf cash $$ to do all that. I do think they have plenty to get to BTD and continue with GLP stuff. That is why I think with Dr. Lbiata's help, we'll get a jv shortly after the BTD.
Comment by Dumbeldorfwhite on Oct 26, 2023 11:14am
I wouldn't expect 5 million to be able to finish the trial, not with 38 patients left, slow enrollment and a 450 final follow up. Expecting more raises IMO and further dilution and pressure in the SP
Comment by Donein25 on Oct 26, 2023 11:25am
with that $5m, add JV $$, add warrant $ and you have more than enough. But you knew that already...you just want to scare folks with talk of "more raises and further dilution and pressure". But you can't scare the science out of us. You got nothing when it comes to CR. 
Comment by Rumpl3StiltSkin on Oct 26, 2023 12:08pm
True, we both agree jv up front money and warrants are important. Not there yet though and I don't think we can count on those $5mil C Jan warrants unless we get a quick BTD. :-)
Comment by Rumpl3StiltSkin on Oct 26, 2023 12:11pm
Oh and I'm not here to scare anyone. Check my history, I'm always busting on 'those' guys. This raise isn't that dilutive and it should be the last one. :-)
Comment by Dumbeldorfwhite on Oct 26, 2023 12:19pm
Ya ll been talking JV for 10 years, licensing etc. how have the warrants worked so far? They really seem to be working as far as raising money
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250